Journal
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
Volume 26, Issue 3, Pages 649-+Publisher
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.hoc.2012.02.012
Keywords
Poly(ADP-ribose) polymerase; Inhibitor; Synthetic lethality; BRCA
Categories
Funding
- Intramural NIH HHS [Z99 CA999999] Funding Source: Medline
- NCI NIH HHS [Y99 CA999999] Funding Source: Medline
Ask authors/readers for more resources
Recently, the development of poly(adenosine diphosphate ribose) polymerase (PARP) inhibitors as a synthetic lethality approach has brought a major breakthrough in the treatment of breast cancer susceptibility gene (BRCA)-mutant cancers. Because sporadic cancers have also been found to commonly have other defects in DNA repair, PARP inhibitors are under active clinical investigation in combination with DNA-damaging therapeutics in a wide range of sporadic cancers. In this review, the authors discuss DNA repair mechanisms and PARP as a therapeutic target and summarize an update on clinical trials of available PARP inhibitors and predictive biomarkers for their efficacy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available